玻璃体视网膜淋巴瘤诊断及推荐治疗中国专家共识(2024年版)

Chinese expert consensus recommendations for the diagnosis and treatment of vitreoretinal lymphoma(2024)

玻璃体视网膜淋巴瘤(VRL)是一类少见的、高级别(即侵袭性)的淋巴结外淋巴瘤,其临床表现缺乏特异性,诊断困难,治疗策略不一致,对患者视力和生存均不利,也进一步限制了该领域的发展。中国抗癌协会眼肿瘤专委会和中国医药教育学会眼科专委会专家针对国内VRL领域实际情况,参考国内外最新研究数据和建议,经反复讨论,制定《玻璃体视网膜淋巴瘤诊断及推荐治疗中国专家共识(2024年版)》。该共识围绕VRL的临床表现、辅助检查、诊断流程、鉴别诊断、治疗及随访策略等方面分别给出意见,为临床医生诊断和治疗VRL提供参考,以进一步提高我国VRL的诊疗水平。

Vitreoretinal lymphoma(VRL)is a rare and highly aggressive extranodal lymphoma with non-specific clinical features,making it difficult to diagnose and treat consistently.This poses a significant risk to both the patient's vision and survival that hinders the development of this field.To address this issue,experts from the Ocular Oncology Committee of China Anti-Cancer Association and Ophthalmological Society of China Medicine Education Association have formulated the Chinese expert consensus recommendations for the diagnosis and treatment of vitreoretinal lymphoma(2024)based on the latest research data and consensus recommendations for the disease.The consensus provides opinions on the clinical manifestations,auxiliary examination,diagnosis,differential diagnosis,treatment,and follow-up strategies of VRL,which serve as references for clinicians to improve the diagnosis and treatment level of this disease in China.